USE OF BREAKERS OF ADVANCED GLYCATION ENDPRODUCTS FOR TREATING DELETERIOUS EFFECTS OF AGING AND DEBILITATING DISEASES

摘要

Advanced glycation endproducts (AGEs) have been implicated in the pathogenesisof a variety of debilitating diseases such as diabetes, atherosclerosis,Alzheimer's and rheumatoid arthritis, as well as in the normal aging process.Seven compounds are here reported to be active in breaking AGE-protein cross-links. These compounds are 1,4-benzene-bis[4-methyleneamino-phenoxyisobutyricacid] (LR102); 4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoicacid (LR99); L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine] (LR20); 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylicacid (LR23); methylene bis [4,4'-(2-chlorophenylureidophenoxyisobutyric acid)](LR90); 5-aminosalicylic acid (5-ASA); and metformin. These compounds may beused to reverse the debilitating effects of those diseases in which AGEs areformed.